Latest news
Dr Thomas on the Safety Profile of Frontline Ipatasertib Plus Pembrolizumab in HNSCC - OncLiveOncLive · Thu, 06 Aug 2026 21:37:16 GMTOvercoming Immunotherapy Resistance in Liver Cancer - the-scientist.comthe-scientist.com · Tue, 04 Aug 2026 14:48:35 GMTImmune Checkpoint Inhibitors Market Size, Share & Growth, 2034 - Straits ResearchStraits Research · Thu, 30 Jul 2026 06:55:57 GMT